Background. Unique characteristics, impact of therapy with antifungal agents, and outcome of infections with Scedosporium species were assessed in transplant recipients.
with disseminated infections, including those involving the CNS [2, [4] [5] [6] [7] [8] . The natural habitat of a related species-Scedosporium prolificans, considered to be a dematiaceous fungus [9] -is less well characterized, although the latter is also a soil saprophyte. The spectrum of infections with S. prolificans ranges from localized infections involving the bone and joints (usually in immunocompetent individuals) to disseminated infections (most commonly found in neutropenic patients) [10] [11] [12] .
Scedosporium species are increasingly recognized as significant pathogens, particularly in immunocompromised hosts. These fungi now account for ∼25% of all non-Aspergillus mold infections in organ transplant recipients [13] . Scedosporium species are generally resis- 
METHODS
The present study includes 13 cases of Scedosporium infection in transplant recipients at our institution (table 1) and cases of scedosporiosis in the literature in patients who had undergone transplantation and patients who had not. For cases in the literature, the MEDLINE database was searched for articles published during 1985-2003 that used the terms "Scedosporium apiospermum" and "Scedosporium prolificans." Additional search terms included "Pseudallescheria boydii," "Allescheria boydii," "Monosporium apiospermum," "Petriellidium boydii," and "Scedosporium inflatum." The latter terms refer to prior or other nomenclature for the 2 Scedosporium species. Additional cases were identified by review of the bibliographies of the original articles.
The search was limited to articles published in 1985 or after to accurately reflect the current trends in immunosuppressive regimens and clinical practices and to include cases involving traditional antifungal therapy (e.g., amphotericin B therapy) for comparison with those cases involving receipt of newer drugs (e.g., the triazole agents). Furthermore, although S. apiospermum has been known to be a pathogen since the early 1900s, most early case descriptions have been descriptions of mycetoma. Finally, S. prolificans was not recognized as a human pathogen until 1984. Two of the authors (S.H. and N.S.) independently extracted the data for cases in the literature. Cases were included if mycologic identification of the fungus was confirmed by culture and evidence of invasive infection was documented. Dissemination was defined as isolation of the fungus from blood cultures, CNS involvement, or infection of у2 noncontiguous sites. Determination of the time to onset after receipt of transplant was made on the basis of individually detailed cases; summarized data, in which only a mean or a range for a cohort of patients was provided, were excluded from this analysis. Time to onset of infection for patients who received a transplant after 1999 was compared with that for those who received a transplant in 1999 or thereafter. Changes in the epidemiologic characteristics of invasive aspergillosis in organ transplant recipients have previously been documented using similar intervals as a cut-off [16] .
Statistical analysis. Categorical variables were compared using Fisher's exact test or x 2 test. Continuous variables were compared using Student's t test (e.g., for age) or the MannWhitney U test (e.g., for time to onset of infection). A logistic model was developed to assess the effect of primary antifungal therapy on mortality. Factors significantly associated with outcome (i.e., presence of disseminated infection and receipt of adjunctive surgery) were added to the model. Treatment was added to the model as an indicator variable set, with amphotericin B as the comparison group. Patients who did not receive antifungal therapy were excluded from the model. Stata software, version 7.0 (Stata), was used for all statistical analysis.
RESULTS
A total of 80 cases of Scedosporium infection in transplant recipients were identified; these comprised 57 cases involving organ transplant recipients (including 13 cases at our institutions) and 23 cases involving HSCT recipients [1, 2, 5, 12, 15, . An additional 190 cases in non-transplant recipients were identified using similar search criteria [3-9, 11, 12, 15, 21, 29, 37, 39, 40, 47, 52, 56, 59-154] , and these cases are discussed primarily to discern the unique characteristics of scedosporiosis in transplant recipients, compared with other hosts.
Epidemiologic and demographic characteristics. Of 57 organ transplant recipients, 20 (35%) were renal transplant recipients (including 3 kidney-pancreas transplant recipients), 16 (28%) were heart transplant recipients (including 5 heart-lung transplant recipients), 10 (18%) were liver transplant recipients, 8 (14%) were lung transplant recipients, and 3 (5%) were small bowel transplant recipients. Fifty-five percent of the patients had received cyclosporine A, 36% had received tacrolimus, and 9% were receiving azathioprine without a calcineurin-inhibitor agent (table 1). All but one of the organ transplant recipients were receiving corticosteroids at the onset of infection. Fortynine percent had previously experienced rejection episodes, and 18% had received prior antifungal prophylaxis (table 2) . In all, 44 (83%) of the 53 infections in organ transplant recipients were due to S. apiospermum, and 10 (19%) were due to S. prolificans (in 4 cases, the Scedosporium isolate was not speciated). The median time from transplantation to onset of infection among organ transplant recipients was 4 months (range, 0.5-158 months) for patients with S. apiospermum infection and 2.6 months (range, 1-17 months) for patients with S. prolificans infection (table 2) .
Of 23 HSCT recipients, the type of stem cell transplantation was not specified for 2 patients; among the remaining 21 HSCT recipients, 15 (71%) received allogeneic and 6 (29%) received autologous transplants. Sixty-seven percent of the HSCT recipients were neutropenic, and 52% had previously had graftversus-host disease. HSCT recipients, compared with organ transplant recipients, were significantly more likely to have received prior antifungal prophylaxis (64% vs.17%; ), P p .001 to be neutropenic (67% vs. 9%;
), and to have infec-P ! .0001 tions due to S. prolificans (39% vs. 17%; ) (table 2) . P p .045 Scedosporium infections occurred significantly earlier after transplantation in HSCT recipients, compared with organ transplant recipients (median time to onset, 1.3 vs. 4 months;
). This difference may be related to the fact that neu-P p .007 tropenia occurred in HSCT recipients at the same time interval.
Overall, 75% of the infections in HSCT recipients and 61% of the infections in organ transplant recipients occurred within 6 months after transplantation.
Patients who received transplants after 1999 (the current cohort) were associated with a significantly longer time to onset of Scedosporium infections after transplantation (median time to onset, 6 months), compared with those who received transplants in 1999 or earlier (the earlier cohort; median time to onset, 1.2 months;
). Eighty-two percent of all Sce-P p .002 dosporium infections in the earlier cohort occurred within 6 months after transplantation, but in the current cohort, only 51% of Scedosporium infections occurred within 6 months ( ). For S. apiospermum infections, the median time to P p .02 onset after transplantation was 5 months in the current cohort, compared with 2.6 months in the earlier cohort ( ). For P p .07 S. prolificans infections, the median time to onset was 4.3 months in the current cohort and 1.0 month in the earlier cohort ( ). P p .04 Clinical manifestations. In all, 23 (46%) of 50 Scedosporium infections in organ transplant recipients were disseminated. CNS, pulmonary, and cutaneous involvement were present in 29%, 43%, and 31% of the organ transplant recipients, respectively. Other infections included those of the eye (4 patients), those of the peritoneum/abdomen (3), cardiac infections (2), mycotic aneurysm infections (2), and a sinus infection ). Disseminated infection and CNS, pulmonary, and P p .009 cutaneous involvement were present in 69%, 36%, 41%, and 36% of HSCT recipients, respectively. Endocarditis, mycotic aneurysm, eye infection, and joint infection were documented in 1 patient each. Fungemia was present in 7 (33%) of 21 HSCT recipients, compared with 6 (11%) of 56 organ transplant recipients ( ). P p .04 When stratified by underlying host disease, transplant recipients differed significantly from other immunosuppressed hosts with respect to the frequency of disseminated infection, fungemia, and pulmonary and skin involvement, but not with respect to CNS infection (table 3) . CNS involvement was present in 15% of the HIV-infected patients, 17% of the immunocompetent patients, 20% of the patients with hematologic malignanies, 25% of organ transplant recipients, and 30% of HSCT recipients ( ). Sepsis-like syndrome with hypoten-P 1 .05 sion was documented exclusively in patients with hematologic malignancy and in HSCT recipients (in 17% and 5%, respectively); it was not documented in other immunosuppressed hosts (table 3) . Thirteen percent of all neutropenic patients were hypotensive, compared with 2.4% of the nonneutropenic patients ( ). P p .005 Outcome. The mortality rate among all transplant recipients with scedosporiosis was 58% (46 of 79). The mortality rate among organ transplant recipients was 54% (31 of 57) (77.8% for patients with S. prolificans infection, and 54.5% for patients with S. apiospermum infections). Amongst HSCT recipients, the overall mortality rate was 68% (15 of 22 ) independently influenced the outcome. P p .02 The use of voriconazole, when controlled for these 2 variables, continued to be associated with a trend towards better survival ( ) . P p .08
When mortality was analyzed for transplant recipients with S. apiospermum infections only, disseminated infection (P ! ) and CNS involvement ( ) were significantly as-.001 P p .013 sociated with greater mortality. In a logistic regression model, using those receiving amphotericin B treatment as the comparison group, survival was greater among those receiving voriconazole, but this difference did not attain statistical significance (OR, 4.7; 95% CI, 0.54-40.9;
). Only P p .15 disseminated infection (OR, 0.10; 95% CI, 0.20-0.47; P p ) independently predicted lower survival. .003
Of 18 transplant recipients with S. prolificans infection, 14 died. Fungemia ( ) and earlier onset of infection after P p .023 transplantation ( ) correlated with a higher mortality P p .053 rate. Of 13 patients treated with amphotericin B, 11 died. Three patients, 1 of whom died, had received voriconazole. These numbers, however, were too small for logistical modeling.
DISCUSSION
There are several observations that can be made from our study with regard to Scedosporium infections in immunocompromised hosts in general and in transplant recipients in particular. Patients with hematologic malignancy and with neutropenia were more susceptible to infections due to S. prolificans than to infections due to S. apiospermum. Indeed, 49% of S. prolificans infections in all hosts and 62% of such infections in immunocompromised patients were in patients with hematologic malignancy (table 3) . Innate immune defenses comprising phagocytic responses play a critical role in host defense against S. prolificans. In one study [155] , mononuclear cell-mediated hyphal damage did not differ among strains of S. prolificans and Aspergillus fumigatus; however, polymorphonuclear cells tended to induce more damage to S. prolificans hyphae than to A. fumigatus. Furthermore, hyphal damage mediated by the triazole antifungal agents against S. prolificans was synergistically enhanced by polymorphonuclear leukocytes [156] . On the other hand, of immunosuppressed hosts, organ transplant recipients and patients receiving corticosteroids had the highest frequency of S. apiospermum infections.
Mold infections are frequently disseminated, particularly in immunosuppressed hosts. The risk for dissemination, however, varies for different mycelial fungi and with the type of transplant. In cases of Aspergillus infection, dissemination occurs in 10%-34% of HSCT recipients and in 9%-35% of organ transplant recipients [16, 157] . Higher rates, approaching 50%, have been reported in liver transplant recipients [16] . We show that 69% of the Scedosporium infections in HSCT recipients and 46% of such infections in organ transplant recipients were disseminated. Scedosporium species, unlike Aspergillus species, have adventitial forms capable of in vivo sporulation, which may facilitate hematogenous spread [30] .
Fungemia was significantly more likely with S. prolificans infection; 57% of S. prolificans infections but only 8% of the S. apiospermum infections in transplant recipients were associated with fungemia ( ). Fungemia occurred more fre-P ! .0001 quently in HSCT recipients, compared with organ transplant recipients ( ). That HSCT recipients were more likely P p .04 to have S. prolificans infections-a species more likely to be associated with fungemia-may account for this observation. It is also plausible that host defense defects that occur in HSCT recipients as a result of neutropenia have a more profound impact on the susceptibility and severity of scedosporiosis than do the immune deficits in organ transplant recipients.
Scedosporium infections may occasionally present with shock and sepsis-like syndrome [10] . Such a presentation was ob-served exclusively in patients with hematologic malignancy or in HSCT recipients and was more common in patients with S. prolificans infections than in those with S. apiospermum infections (13% vs. 1%;
). In an animal model, S. prolificans P ! .0001 strains have been shown to be more virulent than S. apiospermum strains [158, 159] . Whereas mortality associated with S. prolificans infections was significantly higher in mice that were immunosuppressed with hydrocortisone than in immunocompetent mice, no difference in mortality associated with S. apiospermum infection was observed in the 2 groups of animals [158] .
We show that the time elapsed from transplantation to onset of Scedosporium infection in transplant recipients has increased in recent years. These trends largely parallel those reported for invasive aspergillosis in HSCT recipients and organ transplant recipients [16, 160] . It is possible that more frequent use in recent years of antifungal prophylaxis with amphotericin B or itraconazole after transplantation could have delayed the onset of these infections. Antifungal prophylaxis could also have selected for Scedosporium species, because these fungi have been known to emerge as pathogens in patients receiving amphotericin B, fluconazole, or itraconazole [43, 57, 100] . Our data show that, although transplant recipients receiving antifungal prophylaxis tended to have later onset of Scedosporium infections, compared with those who did not receive antifungal prophylaxis (median time to onset, 4 vs. 2.3 months), the proportion of patients who had received antifungal prophylaxis in the current cohort (38%) did not differ significantly from that in the earlier cohort of patients (40%). Whether prolonged survival of transplant patients, delayed occurrence of other riskfactors (e.g., graft-versus-host disease), or as-yet poorly defined factors account for the increase in time before onset of Scedosporium infection after transplantation remains to be determined.
Scedosporium species are resistant or have erratic susceptibility to the polyene antifungal agents, such as amphotericin B. The newer triazoles agents, however, have demonstrated superior activity against S. apiospermum [14, [161] [162] [163] [164] . Voriconazole was more potent than amphotericin B, fluconazole, 5 flucytosine, itraconazole, and ketoconazole [161, 163, 164] . The MIC of voriconazole for S. apiospermum isolates has ranged from 0.12-0.5 mg/mL [162, 163, 165] . The newer triazoles (ravuconazole, posaconazole, and voriconazole) were all active against S. apiospermum, with geometric mean MICs of 0.125, 0.08, and 0.06 mg/mL, respectively; none of these agents had an MIC 10.25 mg/mL for any strain [164] . Cross-resistance was found among all azoles except posaconazole, suggesting that, for S. apiospermum, the mechanism of action for (or resistance to) posaconazole might be different than that for the other azoles [163] . The echinocandins also have some activity against S. apiospermum, with MICs ranging from 0.25-4 mg/mL [166, 167] . S. prolificans, on the other hand, is largely resistant to currently available antifungal agents. Voriconazole has shown some in vitro activity, however, and the investigational triazole UR-9825 (Uriach Laboratories) has had good activity against S. prolificans [163, 164] . A combination of terbinafine and voriconazole was synergistic in vitro [168] .
Profound and often irreversible immunosuppression in the host, frequent occurrence of disseminated infection, and lack of an effective antifungal therapy render Scedosporium infections among the most difficult invasive mycoses to treat. Overall, the mortality rate for transplant recipients with Scedosporium infections was 58% in our study. When adjusted for disseminated infection, therapy with voriconazole, compared with amphotericin B therapy, was associated with a lower mortality rate, a difference that approached statistical significance ( ). The mortality rates associated with treatments with P p .06 itraconazole and other antifungal agents, however, were not significantly different from those associated with treatment with amphotericin B. When included in the logistic regression model, receipt of adjunctive surgery independently portended a better survival rate among transplant recipients with scedosporiosis (table 4) . A potential bias may nonetheless have existed in the selection of patients to undergo surgical debridement (e.g., they may have been selected because of better performance status or because they had a removable focus of infection). However, the use of voriconazole therapy, compared with amphotericin B therapy, continued to be associated with a trend towards lower mortality, even when controlled for surgery and disseminated infection.
In summary, Scedosporium infections in transplant recipients were associated with a high rate of dissemination; were associated with a later onset in patients who received a transplant in recent years, compared with those who received a transplant earlier; and were associated with an overall dismal outcome. HSCT recipients, compared with organ transplant recipients, were more likely to have S. prolificans infections and fungemia. The use of voriconazole therapy appeared to portend a better outcome. We caution, however, that these data are based on a small number of patients and are limited by bias inherent to anecdotal reporting of cases in the literature. Nevertheless, given the in vitro activity of the newer triazole agents, these drugs warrant consideration as a preferred therapeutic modality for Scedosporium infections.
